FADS2 and thyroid gland carcinoma: A higher FADS2 expression has been associated with reduced OS in BLCA, KIRP, LUSC, PCPG, mesothelioma (MESO), thyroid carcinoma (THCA), and uveal melanoma (UVM) (Fig. 4).